Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
РУДН, Москва
Список исп. литературыСкрыть список 1. Аведисова А.С., Будтуева Ф.С., Григорьева О.В. Новые возможности применения атипичного антипсихотика Сероквеля. РМЖ. 2010; 26: 1558–61. 2. Бурлаков В.А. К проблеме лечения шизофрении, протекающей с сенестоипохондрическими нарушениями (опыт применения Сероквеля). Психиатр. и психофармакотер. 2003; 2: 106–9. 3. Бурчинский С.Г. Нейролептики в фармакотерапии биполярных аффективных расстройств: возможности выбора. НейроNews: психоневрол. и нейропсихиатр. 2009; 6. http://www.neuro.health-ua.com/article/203.html 4. Гурович И.Я., Шмуклер А.Б., Магомедова М.В. и др. Помощь больным шизофренией с первыми психотическими эпизодами: применение кветиапина. Соц. и клинич. психиатр. 2004; 3: 69–72. 5. Иванов М.В., Мазо Г.Э., Чомский А.Н. и др. Сероквель: перспективы и опыт терапии маний при биполярных аффективных расстройствах. Обозр. пихиатр. и мед. психол. им. В.М.Бехтерева. 2004; 4: 5–7. 6. Ильина Н.А. Терапия шизофрении и шизоаффективных расстройств: опыт применения кветиапина (сероквеля). Психиатр. и психофармакотер. 2004; 6: 276–82. 7. Калинин В.В. Применение препарата Сероквель (кветиапин) для лечения больных шизофренией. Психиатр. и психофармакотер. 2005; 2: 34–8. 8. Калинин В.В. Сероквель – атипичный нейролептик: особенности психотропного эффекта и показания. Психиатр. и психофармакотер. 2001; 5. 9. Любов Е.Б., Чапурин С.А., Чурилин Ю.Ю. Фармакоэкономическая модель антирецидивного лечения Сероквелем, Рисполептом и Зипрексой пациентов в первом эпизоде шизофрении. Психиатр. и психофармакотер. 2005; 4: 193–8. 10. Мазо Г.Э. Влияние терапии Сероквелем на депрессивную симптоматику в структуре шизофрении. Психиатр. и психофармакотер. 2003; 6: 259–62. 11. Малин Д.И. Место нейролептической терапии в лечении биполярного аффективного расстройства. 2004; 5: 236–8. 12. Малин Д.И. Эффективность кветиапина (сероквеля) в лечении острых психозов при адекватном дозировании. Психиатр. и психофармакотер. 2005; 3: 149–51. 13. Медведев В.Э. Кветиапин при терапии биполярного аффективного расстройства. Психиатр. и психофармакотер. 2010; 5: 14–9. 14. Мосолов С.Н. Полвека нейролептической терапии: основные итоги и новые рубежи. Новые достижения в терапии психических заболеваний. М., 2002. 15. Мосолов С.Н., Александровский Ю.А., Вовин Р.Я. и др. Новый атипичный антипсихотик Сероквель. Результаты российских клинических испытаний. Психиатр. и психофармакотер. 1999; 2: 16–24. 16. Смулевич А.Б., Зеленина Е.В. Терапия маниакальных и маниакально-бредовых состояний (клинические эффекты Сероквеля). Психиатр. и психофармакотер. 2005; 1: 20–4. 17. Ястребов Д.В. Клиническое применение препарата сероквель. Фарматека. Неврология. Психиатрия. 2005; 17 (112): 112. 18. Ahlfors UG, Baastrup PC, Dencker SJ et al. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr Scand 1981; 64 (3): 226–37. 19. Altshuler LL, Gitlin MJ, Mintz J et al. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry 2002; 63: 807–81. 20. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision). Am J Psychiatry 2002; 159. 21. Apter JT, Cantillon M. Efficacy, safety, and tolerability of Seroquel (quetiapine fumarate) in elderly patients with psychotic disorders. Abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology 1997; 295. 22. Arango C, Bobes J. Managing acute exacerbation of schizophrenia: focus on quetiapine. Curr Med Res Opin 2004; 5: 19–26. 23. Arvanitis LA, Miller BG. the Seroquel Trial 13 study group. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233–46. 24. Avnon M, Goldin V, Neissburg J. Two long-term neuroleptic resistant patients treated by Seroquel (JCJ 204636) an atypical neuroleptic. Eur Neuropsychopharmacology 1996; 6: 54–124. 25. Audinot V, Canton H, Newman-Tancredi A et al. In vitro and ex vitro patterns of occupation of 5-HT2A and alpha-1-adrenergic as compared to dopamine D2-receptors by novel antypsychotics. Eur Neuropsychopharmacology 1995; 3: 330. 26. Bartko G, Varadi H, Simon L et al. Patient satisfaction after switching from conventional to new atypical antipsychotics in schizophrenia. Int J Psychiatry Clin Pract 2002; 6: 9–14. 27. Brecher MM, Huizar K. Quetiapine monotherapy for acute mania with bipolar disorder. Presented at the 27th Nordic Psychiatric Congress, Aug 13–16 2003; Reykjavik, Iceland. 28. Bobes J, Garcia-Portilla MP, Saiz PA et al. High degree of tolerability for monotherapy with high doses of quetiapine: a case report. J Clin Psychiatry 2002; 63: 1048–9. 29. Calabrese JR, Bowden CL, Sachs GS et al. A double-blind placebocontrolled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79–88. 30. Calabrese JR, Keck PE, Macfadden W et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II Depression. Am J Psychiatry 2005; 162: 1351–60. 31. Casey D. Seroquel (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 1996; 8: 939–57. 32. Chengappa KNR, Goldstein JM, Greenwood M et al. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 2003; 25: 530–41. 33. Chengappa KNR, Parepally H, Brar JS et al. A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study. Can J Psychiatry 2003; 48: 187–94. 34. Copolov DL, Link CGG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204, 636 Seroquel) and haloperidol in schizophrenia. Psychol Med 2000; 30: 95–105. 35. Del Bello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41: 1216–23. 36. De Nayer A, Windhager E, Irmansyah F et al. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract 2003; 7: 59–66. 37. Emsley RA, Raniwalla J, Bailey PJ et al. A comparison of the effects of quetiapine (Seroquel) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 2000; 15: 121–31. 38. Fabre L, Arvanitis L, Pultz J et al. Seroquel (quetiapine) (JCJ 204636), a novel atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenic. Clin Therapeutics 1995; l7 (3): 366–78. 39. Fleischhacker W, Linkz C, Hurst B. JCJ-204636 (Seroquel) – a putative new atypical antipsychotic: results from phase III trials. Schizophr Res 1996; 2 (3): 132. 40. Fulton B, Goa K. JCJ-204636. An initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia. CNS Drugs 1995; 1: 68–78. 41. Gefvert O, Lindstrom L, Langstrom B et al. Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg. Seroquel TTD. Eur Neuropsychopharmacology 1996; 6: 74. 42. Ghaemi SN, Goldberg JF, Henry CA et al. Quetiapine for rapid-cycling bipolar disorder: a long-term follow-up study (abstract). Bipolar Disord 2003; 5 (Suppl. 1): 50. 43. Goldstein J. Preclinical profile of Seroquel (quetiapine): an atypical antipsychotic with clozapine-like pharmacology. Schizophrenia: Breaking down the barriers. Ed. Holliday S., Ancil R. and Mac Ewan G 1996; l77–208. 44. Goldstein J, Arvanitis L. JCJ-204636 (Seroquel): a dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drugs Reviews. 1: 50–73. 45. Goodwin GM. Consensus Group of the British Association for Psychopharmacology: Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17: 149–73. 46. Goodwin F, Jamison K. Manic-Depressive Illness. New-York, Oxford University Press, 1990. 47. Harmon T, Krenzelok E. Rapid loss of consciousness from acute quetiapine overdosage. Journal of Toxicology – Clinical Toxicology 1997; 35 (5): 546. 48. Hellewell JSE, Kalali AH, Langham SJ et al. Patient satisfaction and acceptability of long-term treatment with quetiapine. Int J Psychiatry Clin Pract 1999; 3: 105–13. 49. Hirsch S, Link C, Goldstein J et al. JCJ-204636: A new atypical antipsychotic drug. Br J Psychiatry 1996; 168 (Suppl. 29): 45–56. 50. Hirschfeld RM. The efficacy of atypical antipsychotics in bipolar disorders. J Clin Psychiatry 2003; 64 (Suppl. 8): 15–21. 51. Janicak PG, Davis JM, Ayd F et al. The Pharmacology of Bipolar Disorders. In: Janicak PG et al. Principles and practice of psychopharmacotherapy. Update 3. Baltimore: Williams & Wilkins 1995. 52. Jones M, Huizar K. Practice guideline for the treatment of patients with bipolar disorders (revision). Am J Psychiatry 2002; 159: 1–50. 53. Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60: 261–9. 54. Kaplan Н, Sadock B. Comprehensive Textbook of Psychiatry 4th edn 1996. 55. Lapin IP, Oxenkrug GF. Intensification of the central serotoniner process as a possible determinant of the thymoleptic effect. Lancet 1969; 1: 132–6. 56. Link C, Arvanitis L, Miller B et al. A multicentre, placebo-controlled, double-blind evaluation of Seroquel in hospitalised patients with acute exacerbation of chronic and subchronic schizophrenia. Eur Neuropsychopharm 1994; 4 (3 Spec. Jss): 385–6. 57. Link С, Smith A, Miller В et al. A multicentre, double-blind, controlled comparison of Seroquel and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia. Eur Neuropsychopharm 1994; 4 (3 Spec. Jss): 385. 58. McIntyre RS, Brecher M, Paulsson B et al. Quetiapine or haloperidol as monotherapy for bipolar mania – a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. European Neuropsychopharmacology 2005; 15: 573–85. 59. McManus DQ, Rak IW. Safety and Tolerability of Seroquel (Quetiapine) in Elderly Subjects with Psychosis. Neurology 1997; 48: 100. 60. Meats P. Quetiapine (Seroquel): an effective and well-tolerated atypical antipsychotic. Int J Psychiatry in clinical practice 1997; 4: 231–9. 61. Mullen JA, Devine NA, Sweitzer DE. Quetiapine versus placebo as adjnct to Lithium or Divaloproex for the treatment of bipolar disorder. Presented at the Psychiatric Congress: Quetiapine and Bipolar Affective Disorders 2003; 14–17. Kanne, France. 62. Nudelman E, Vinuela LM, Cohen CI. Safety in Overdose of Quetiapine: A Case Report. Journal of Clinical Psychiatry 1998; 59 (8): 433. 63. Paulsson B, Huizar K. Quetiapine monotherapy for treatment of bipolar disorder. Presented at the Psychiatric Congress: Quetiapine and Bipolar Affective Disorders 2003; 14–17. Kanne, France. 64. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63: 1121–8. 65. Post RM, Leverich GS, Altshuler LL et al. An overview of recent findings of the Stanley Foundation Bipolar Network (part I). Bipolar Disord 2003; 5: 310–9. 66. Pollack PT, Zbuk K. Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. Clin Pharmacol Ther 2000; 68 (1): 92–7. 67. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001; 26: 137–49. 68. Robinson С, Robinson К, Castaner J. Quetiapine Fumarate. Drugs of the Future 1996; 5: 483–9. 69. Sachs G, Chengappa KN, Suppes T et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004; 6: 213–23. 70. Sacts GS, Printz DJ, Kahn DA et al. The Expert Consensus Guide Line Series: Medication Treatment of Bipolar Disorders. Posgaded Med 2000; 1: 104. 71. Sailer C, Salama A. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993; 3: 285–92. 72. Sajatovic M, Brescan DW, Periz DE et al. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry 2001; 62: 728–32. 73. Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 2002; 63: 1156–63. 74. Seroquel: a putative atypical antipsychotic drug with serotonin- and dopamine-receptor antagonist properties. J Clin Psychiatry 1995; 9: 438–45. 75. Shimada E, Murasaki M, Miura S et al. A phase I study in healthy volunteers of JCJ-204636, a novel neuroleptic agent. Can J Physiol Phannacol 1994; 72 (Suppl. 1): 445. 76. Simons WR, Bassi R, White R. Antipsychotic compliance evaluation: a population-based managed care study of persistence with initially prescribed antipsychotic medication. International Society for Pharmacoeconomics and Outcomes Research 4th Annual European Congress 2001; 11–13. Cannes, France. 77. Simons WR. Persistency and Compliance Evaluation (PACE): a US population-based analysis of persistency with initially prescribed antipsychotics. College of Psychiatric and Neurologic Pharmacists 6th Annual Meeting, Charleston, South Carolina, USA 2003; 1–4. 78. Seemuller F, Forsthoff A, Dittmann S et al. The safety and tolerability of atypical antipsychotics in bipolar disorder. Expert Opin Drug Saf 2005; 4 (5): 849–68. 79. Smith MA, McCoy R, Hamer J, Brecher M. Optimal titration for quetiapine: pilot trial. College of Psychiatric and Neurologic Pharmacists 5th Annual Meeting, Seattle, Washington, USA 2002; 18–21. 80. Smith MA, McCoy R, Hamer J et al. Rapid dose escalation with Quetiapine. Journal of Clinical Psychopharmacology 2005; 25: 331–5. 81. Stahl S. Psychopharmacology of antipsychotics. Martin Dunitz Ltd, London 1999; 148. 82. Sverdlov NR. Dopamine and depression: circuitas logic? J Biol Psychiatry 1993; 33: 751–8. 83. Suppes T, McElroy SL, Keck PE et al. Use of quetiapine in bipolar disorder: a case series with prospective evaluation. Int Clin Psychopharmacol 2004; 19: 173–4. 84. Targum SD, Criden MR. Efficacy of Seroquel (Quetiapine) in Parkinson\'s Patients With Psychosis. Movement Disorders 1997; 12 (5): 842–3. 85. Thase ME, Macfadden W, Weisler RH et al. Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression. A Double-blind, Placebo-controlled Study (The BOLDER II Study). J Clin Psychopharmacol 2006; 26: 600–9. 86. Vieta E, Mullen J, Brecher M et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 2005; 21: 923–34. 87. Vieta E, Parramon G, Padrell E et al. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 2002; 4: 335–40. 88. Wetzel H, Szegedi A, Hain C et al. Seroquel (JCJ-204636), a putative atypical antipsychotic in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEY parameters. Psychopharmacology 1995; 119 (2): 231–8. 89. Wong Y, Ewing B, Jaskiw G et al. Multiple-doses of Seroquel (quetiapine) in elderly psychotic patients. 149th Annual meeting of АРА. N.-Y. 1996; 4–9. 90. Yeang PP, Goldstein JM, Hellewell JSE. Extrapyramidal Symptoms in General and Elderly Psychotic Patients Population. Presented at the Psychiatric Congress: Quetiapine and Bipolar Affective Disorders 2003; 14–17. Kanne, France. 91. Zarate CA, Rothschild A, Fletcher KE et al. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000; 61: 185–9. 92. Zornberg GL, Pope HG. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993; 13: 397–408.